Parasitic Diseases: Clinical Trials

269 trials for Parasitic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

188 completed, 36 unknown, 13 recruiting, 12 terminated. 269 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4269Completed 188, Unknown 36, Recruiting 13, Terminated 12, Withdrawn 10, Not yet recruiting 7, Suspended 2, Active not recruiting 1

Follow Parasitic Diseases: new trials by email Literature Review of Parasitic Diseases trials Research Report on Parasitic Diseases

Trials (filtered) newest first · largest first

All 269 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria
Coartem® Baby - Malaria
Phase 4Not yet recruitingNovartis Pharmaceuticals202027-06-182026-07-20
Humanitarian Evaluation of Spatial Emanators for Malaria Control
Guardian™ long-lasting spatial emanators - Malaria Infection
Phase 4Not yet recruitingThe Mentor Initiative325842026-10-262026-10-21
Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission
dihydroartemisinin-piperaquine - Malaria
Phase 4RecruitingUniversity of California, San Francisco48002026-09-222026-11-12
Perennial Malaria Chemoprevention in the Malaria Vaccine Era
Sulfadoxine pyrimethamine + Amodiaquine, Dihydroartemisinin Piperaquine, Dihydroartemisinin Piperaquine Placebo - Malaria, Falciparum
Phase 4Not yet recruitingStanford University12902026-09-012026-01-07
R21/MM Dosing, Presentations, and Preservatives
10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative - Plasmodium Falciparum Malaria, Malaria
Phase 4Not yet recruitingUniversity of Oxford3752026-08-152026-08-04
Tafenoquine and ACTs (TADORE- Plus)
Tafenoquine plus DHA-Piperaquine, Tafenoquine plus Artesunate-pyronaridine - Vivax Malaria
Phase 4Not yet recruitingMenzies School of Health Research5072026-06-012026-03-18
Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria
Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine - Uncomplicated Malaria
Phase 4Not yet recruitingCurtin University602026-04-012026-02-12
OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa
Artemether-lumefantrine (AL), artesunate-amodiaquine (AS-AQ) - Malaria, Hiv
Phase 4RecruitingYale University3802025-12-182026-02-04
Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat - Pharmacokinetics of Tafenoquine
Phase 4RecruitingCurtin University302025-10-202026-03-18
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
Moxidectin, Ivermectin - Onchocerciasis, Ascaris Lumbricoides Infection
Phase 4RecruitingKirby Institute520002025-08-042025-11-21
Post-discharge Malaria Chemoprevention Implementation Trial in Benin
Adherence support strategy A, Adherence support strategy B, Control - Severe Malaria, Severe Anaemia
Phase 4RecruitingInstitut de Recherche Clinique du Benin6482025-07-022026-08-12
Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
"Synchronised" arm (intervention) - Malaria Infection, Malaria Vaccines
Phase 4RecruitingEpicentre700002025-06-162026-04-15
Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months - Malaria Vaccine
Phase 4RecruitingEpicentre400002025-06-102025-08-08
Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
Metronidazole 500 mg, Secnidazole 2000 MG - Trichomonas Vaginitis, Bacterial Vaginitis
Phase 4RecruitingTulane University12002025-05-062026-05-06
Vivax Elimination With Tafenoquine (VET) Study
Tafenoquine - Malaria, Malaria, Vivax
Phase 4CompletedShoklo Malaria Research Unit12422025-02-192026-01-06
Mass Vaccine and Drug Administration, Bangladesh
DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™ - Plasmodium Falciparum Malaria
Phase 4RecruitingUniversity of Oxford100002025-02-152025-12-18
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine-pyrimethamine-amodiaquine - Malaria,Falciparum, Anemia in Children
Phase 4CompletedLiverpool School of Tropical Medicine7882024-10-142026-07-30
Southeast Asia Dose Optimization of Tafenoquine
Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg - Plasmodium Vivax Malaria
Phase 4RecruitingUniversity of Oxford8202024-07-222026-10-09
The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children
Mosquirixs, artemether-lumefantrine - Malaria,Falciparum
Phase 4UnknownKamuzu University of Health Sciences54002024-06-012024-05-21
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
albendazole and praziquantel, Albendazole - Neurocysticercosis
Phase 4Not yet recruitingR-Evolution Worldwide S.r.l. Impresa Sociale3002024-06-012024-04-23

Showing 20 of 269. Sign in to see all of them.

Narrower conditions

Malaria (158)  ·  Malaria, Falciparum (61)  ·  Malaria, Vivax (24)  ·  Anemia (11)  ·  Chagas Disease (8)  ·  HIV Infections (8)  ·  Disease (7)  ·  Scabies (6)  ·  Diarrhea (5)  ·  Elephantiasis, Filarial (5)  ·  Helminthiasis (5)  ·  Leishmaniasis, Visceral (5)  ·  Pneumonia (5)  ·  Trichuriasis (5)  ·  Acquired Immunodeficiency Syndrome (4)

Broader conditions

Infections (268)  ·  Protozoan Infections (233)  ·  Vector Borne Diseases (230)  ·  Mosquito-Borne Diseases (207)  ·  Malaria (44)  ·  Pathological Conditions, Signs and Symptoms (31)  ·  Helminthiasis (23)  ·  Pathologic Processes (21)  ·  Euglenozoa Infections (20)  ·  Hemic and Lymphatic Diseases (20)  ·  Nematode Infections (18)  ·  Urogenital Diseases (17)  ·  Secernentea Infections (16)  ·  Genital Diseases (15)

Interventions

Artemether, Lumefantrine Drug Combination (70)  ·  Primaquine (25)  ·  Chloroquine (23)  ·  fanasil, pyrimethamine drug combination (22)  ·  amodiaquine, artesunate drug combination (19)  ·  Amodiaquine (18)  ·  Artesunate (17)  ·  Albendazole (15)  ·  Ivermectin (11)  ·  Azithromycin (7)  ·  Pyrimethamine (7)  ·  tafenoquine (7)  ·  Mebendazole (6)  ·  Mefloquine (6)  ·  Rapid Diagnostic Tests (6)

Sponsors

London School of Hygiene and Tropical Medicine (19)  ·  Centers for Disease Control and Prevention (13)  ·  University of California, San Francisco (9)  ·  Bandim Health Project (8)  ·  University of Oxford (8)  ·  Menzies School of Health Research (7)  ·  Malaria Consortium (6)  ·  PATH (6)  ·  Epicentre (5)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (5)  ·  Novartis Pharmaceuticals (5)  ·  Sanofi (5)  ·  Albert Schweitzer Hospital (4)  ·  Armed Forces Research Institute of Medical Sciences, Thailand (4)  ·  Karolinska University Hospital (4)

Countries

Tanzania (23)  ·  Uganda (18)  ·  Ghana (15)  ·  Kenya (15)  ·  Burkina Faso (14)  ·  Brazil (13)  ·  Malawi (11)  ·  Vietnam (11)  ·  Ethiopia (10)  ·  Cambodia (9)  ·  Democratic Republic of the Congo (8)  ·  Guinea-Bissau (8)  ·  India (8)  ·  Thailand (8)  ·  Cameroon (7)

Top investigators

Andreas Martensson, PhD (3)  ·  Harry Tagbor, DrPH (3)  ·  Mariusz Wojnarski, MD (3)  ·  Peter Aaby (3)  ·  Salim Abdulla, MD, PhD (3)  ·  Wilfred Fon Mbacham, PhD (3)  ·  Amy D Klion, M.D. (2)  ·  Andreas Martensson (2)  ·  Antonio L Ribeiro, MD, PhD (2)  ·  Brioni R Moore, PhD (2)  ·  Christopher Whitty, FRCP (2)  ·  Dysoley Lek, MD (2)  ·  Francesco Grandesso, MSc (2)

Results publications

PMID 25421474, PMID 18828899, PMID 30860013, PMID 39324693, PMID 11103309, PMID 16163624, PMID 17093247, PMID 17259188, PMID 17383291, PMID 17467344, PMID 17550470, PMID 18008241, PMID 18008242, PMID 18067679, PMID 18503714, PMID 18575626, PMID 18775092, PMID 18831691, PMID 18831737, PMID 19102746, PMID 19127975, PMID 19399156, PMID 19848610, PMID 20207689, PMID 20299957, PMID 20412275, PMID 20675669, PMID 20932805, PMID 2096501, PMID 21148503, PMID 21304921, PMID 21410954, PMID 21423852, PMID 21569596, PMID 21631932, PMID 21838909, PMID 21947399, PMID 22185672, PMID 22189084, PMID 22232457, PMID 22499837, PMID 22514617, PMID 22531245, PMID 22554092, PMID 22882836, PMID 23175563, PMID 23209861, PMID 23212366, PMID 23232458, PMID 23617626

NIH funding

R01HD068174 (3), 5UM1AI148689-03 (1), R01AI103228 (1), R01HD079695 (1), R01HL134211 (1), R01NS064905 (1), U01AI068632 (1), U01AI162463 (1), U01AI186861 (1), U19AI061972 (1)